Valneva’s AGM Greenlights a Fresh Start, but the Stock Remains in the Shadow of a Statistical Miss

Valneva shareholders approve governance changes amid 41% YTD stock drop, as Lyme vaccine LB6V awaits regulatory filing and cost-cutting measures take effect.

Shareholders of the French vaccine developer gathered in Lyon on 25 June and gave the board a clean sweep of approvals, yet the market’s reaction has been one of studied indifference. Valneva’s stock closed the day at €2.27, a stone’s throw from its May low of €2.13 and down nearly 41% since the start of the year. The meeting ratified a move of the company’s registered seat to Lyon — following the closure of its Nantes site — and, more significantly, ushered in a new chairman.

Dr. Gerd Zettlmeissl, an independent director with more than four decades in biopharmaceuticals, takes over the role from Anne-Marie Graffin, who stays on as vice-chair. The assembly also confirmed Thomas Lingelbach for a three-year term as CEO and re-elected Graffin, James Sulat, and Kathrin Jansen for one year, while James Connelly received a two-year mandate. The governance overhaul is meant to signal stability, but Valneva’s share price tells a different story.

The stock now trades a full 35% below its 200-day moving average of €3.52 and well under the 50-day line of €2.39. The relative strength index stands at 42.4, a neutral reading that captures the market’s indecision. Annualised volatility of nearly 32% has offered little comfort to holders.

At the heart of the investment case — and the reason for the stock’s decline from a 52-week high of €5.16 in August 2025 — lies a single product: the Lyme disease vaccine candidate LB6V, formerly VLA15. Developed in partnership with Pfizer, the vaccine delivered strong efficacy data in Phase 3, but the path to approval is anything but straightforward. The first interim analysis missed the pre-specified statistical hurdle, though a second analysis hit it. Pfizer stated in a joint press release on 23 March that it remains confident in the vaccine’s potential and intends to file for regulatory clearance in the second half of 2026. A formal application has yet to be submitted.

Valneva’s CEO has described the regulatory route as “a matter of negotiation,” and neither the FDA nor the EMA has received a complete dossier. The uncertainty leaves investors guessing whether the efficacy evidence will satisfy regulators, especially under a US administration that has signalled stricter oversight.

Meanwhile, the company’s financial picture has deteriorated. First-quarter net loss widened to €32.1 million from €9.2 million a year earlier, hit by one-off manufacturing costs, underutilisation, and lower sales. In response, Valneva has launched a cost-cutting programme that includes a 10–15% reduction in headcount and a 25–35% drop in operating expenses for 2026. Revenue guidance for the full year has been trimmed to €135–150 million from a previous €145–160 million, as the travel-vaccine business softens.

On the cash front, Valneva held €105.3 million at the end of March, before the €37 million gross proceeds from an April capital raise. An additional financing mechanism ties further funds to the Lyme programme: warrants exercisable at €2.96 — contingent on FDA approval — could bring in up to €47 million if fully exercised by September 2028.

The Chikungunya vaccine IXCHIQ remains a drag after Valneva voluntarily withdrew its US application following an FDA licence suspension in August 2025. The company’s pipeline also includes candidates for shigellosis and Zika, but near-term attention stays fixed on Pfizer’s submission timeline.

Analysts are cautious. A TipRanks-derived rating calls the stock a “Sell” with a target of $4.90, citing weak fundamentals, negative free cash flow, and bearish technicals. Chartwise, the shares are wedged between resistance at the 50-day average and support at the year’s low of €2.13. A successful filing could spark a move toward higher analyst targets; a rejection or delay would likely push the stock below that floor.

The next clear milestones are Pfizer’s confirmation of the submission in the second half of 2026 and Valneva’s upcoming quarterly results, which will show whether the travel-vaccine decline has stabilised. For now, the market is waiting — and the new board is hoping the data package to come will be strong enough to break the stock out of its narrow range.